We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Suppressing a Protein in Acute Myeloid Leukemia To Overcome Drug Resistance
News

Suppressing a Protein in Acute Myeloid Leukemia To Overcome Drug Resistance

Suppressing a Protein in Acute Myeloid Leukemia To Overcome Drug Resistance
News

Suppressing a Protein in Acute Myeloid Leukemia To Overcome Drug Resistance

Human cells with acute myelocytic leukemia (AML) in the pericardial fluid, shown with an esterase stain at 400x. Credit: National Cancer Institute
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Suppressing a Protein in Acute Myeloid Leukemia To Overcome Drug Resistance"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

South Australian scientists have made a significant breakthrough in overcoming drug resistance in acute myeloid leukaemia (AML), a rare and devastating blood cancer that kills most patients within a few years.


In a new study published in the world-leading hematology journal Blood, researchers from the University of South Australia and SA Pathology’s Centre for Cancer Biology describe how they have discovered a way to suppress a specific protein that promotes resistance to drugs commonly used to treat AML patients.


Professor Stuart Pitson, one of the lead authors of the study, says the finding could revolutionise the treatment of AML, a disease that has claimed the lives of Australian football great Russell Ebert, professional golfer Jarrod Lyle, high-profile American journalist Nora Ephron and filmmaker Lynn Shelton.


This year, it is estimated that 20,000 people in the United States and 900 people in Australia will be diagnosed with acute myeloid leukaemia, a cancer of the blood and bone marrow characterised by an overproduction of cancerous white blood cells called leukaemic blasts.


Prof Pitson says these cells crowd out normal white blood cells, which then can’t do their usual infection-fighting work, thereby increasing the risk of infections, low oxygen levels and bleeding.


SA Pathology haematologist Associate Professor David Ross says many AML patients initially respond to Venetoclax, a new therapy for AML recently listed on the PBS, but over time AML cells become resistant to it.


Using a large biobank of patient-donated AML biopsies and world-leading advanced pre-clinical models, the CCB researchers demonstrated that by modulating lipid metabolism in the body, a protein called Mcl-1 is inhibited in AML cells – the protein that facilitates drug resistance.


“This process makes AML cells exquisitely sensitive to Venetoclax, while leaving the normal white blood cells unaffected,” SA Pathology researcher and co-lead author, Associate Professor Jason Powell says.


The CCB team is now working hard to optimise drugs targeting this pathway to take into clinical trials for AML patients.


“For most people with AML, the chances of long-term survival are no better now than they were last century,” Assoc Prof Ross says.


“Now, we have a chance to remedy that. New treatments that prevent Venetoclax resistance have the potential to prolong survival, or even increase the chances of a cure in a disease for which improved outcomes are desperately needed.”


Reference: Lewis AC, Pope VS, Tea MN, et al. Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia. Blood. 2022:blood.2021013277. doi: 10.1182/blood.2021013277


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement